Free Trial

Promising Mid Cap Stocks Worth Watching - October 9th

AltC Acquisition logo with Energy background

Key Points

  • AltC Acquisition Corp. is focused on completing a business combination and does not currently have significant operations; it was formerly known as Churchill Capital Corp VIII.
  • Akero Therapeutics, Inc. is advancing its lead product candidate efruxifermin (EFX) through Phase 3 clinical trials for treating metabolic diseases.
  • Direxion Daily TSLA Bull 2X Shares is one of the mid-cap stocks with notable trading volume, appealing to investors for potential growth and volatility.
  • Five stocks to consider instead of AltC Acquisition.

AltC Acquisition, Akero Therapeutics, and Direxion Daily TSLA Bull 2X Shares are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies whose total market value typically falls between about $2 billion and $10 billion. These firms are generally more established than small-caps but still offer higher growth potential (and volatility) than large-cap companies. Investors often include mid-caps in their portfolios to balance growth opportunity with a moderate level of risk. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Read Our Latest Research Report on ALCC

Akero Therapeutics (AKRO)

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Read Our Latest Research Report on AKRO

Direxion Daily TSLA Bull 2X Shares (TSLL)

Read Our Latest Research Report on TSLL

Featured Articles

Should You Invest $1,000 in AltC Acquisition Right Now?

Before you consider AltC Acquisition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AltC Acquisition wasn't on the list.

While AltC Acquisition currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.